MediWound Ltd. to Post FY2017 Earnings of ($0.80) Per Share, SunTrust Banks Forecasts (MDWD)
MediWound Ltd. (NASDAQ:MDWD) – Research analysts at SunTrust Banks dropped their FY2017 earnings per share (EPS) estimates for MediWound in a report issued on Monday. SunTrust Banks analyst B. Nudell now anticipates that the biopharmaceutical company will post earnings per share of ($0.80) for the year, down from their previous forecast of ($0.78). SunTrust Banks currently has a “Buy” rating on the stock. SunTrust Banks also issued estimates for MediWound’s Q4 2017 earnings at ($0.21) EPS.
MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The company had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.69 million. During the same quarter in the previous year, the firm posted ($0.34) EPS. The business’s revenue for the quarter was up 93.8% compared to the same quarter last year.
Several other brokerages have also weighed in on MDWD. Zacks Investment Research lowered shares of MediWound from a “hold” rating to a “sell” rating in a research report on Tuesday. Aegis reaffirmed a “buy” rating and set a $11.00 price target on shares of MediWound in a research report on Thursday, May 25th. Finally, Oppenheimer Holdings, Inc. set a $10.00 price target on shares of MediWound and gave the stock a “buy” rating in a research report on Monday, May 8th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $10.19.
MediWound (NASDAQ MDWD) opened at 6.70 on Thursday. The company’s market cap is $146.93 million. MediWound has a 12-month low of $4.25 and a 12-month high of $8.58. The stock’s 50 day moving average is $6.94 and its 200 day moving average is $6.46.
Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 7,900 shares in the last quarter. Wells Fargo & Company MN raised its position in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares in the last quarter. 27.32% of the stock is currently owned by institutional investors and hedge funds.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.